Posted at 21:30h
in
Uncategorized
Vaccibody AS today announces that the European Patent Office (EPO) has granted European patent No. 1599504 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell responses.
This patent...
Posted at 16:58h
in
Uncategorized
As Vaccibody is entering into a new development phase, the Board of Directors has initiated a search process for a new CEO with experience from clinical development and strategic partnering. On this background, Ole Henrik Brekke, CEO since 2006, has decided to leave the...
Posted at 14:05h
in
Uncategorized
Vaccibody has in a new share issue completed a 35 MNOK (4.3 million €) financing from existing and new investors. The share issue was significantly oversubscribed. The largest new investor is represented by Datum and partners, which will take a seat in the Board of...
Posted at 22:00h
in
Uncategorized
Oslo-, Teaneck, New Jersey, June 2, 2014
The Norwegian vaccine company Vaccibody and Phibro Animal Health Corporation (Nasdaq:PAHC), a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell...
Posted at 08:39h
in
Uncategorized
A report addressing solutions for strengthening the Norwegian biotechindustry was handed over to the Norwegian government May 20th. Vaccibody was the company being exemplified in the accompanying article in Dagens Næringsliv. Read the article here (Norwegian only)....
Posted at 13:53h
in
Uncategorized
The Norwegian Cancer Society (NCS) has recently organized a investment fund for Norwegian companies with a focus on developing novel cancer therapies. With the promising development of VB10.16, Vaccibody’s therapeutic vaccine against HPV induced precancerous lesions, NCS has decided to place their first investment in...
Posted at 13:54h
in
Uncategorized
New targeting vaccines for aquaculture based on the Vaccibody concept won 1st prize in Marine Innovation Day (MID) Innovation Award in a conference held in Bergen early in March.
The vaccineproject run by researchers at the Norwegian Veterinary Institute and University of Oslo aims to utilize...
Posted at 13:55h
in
Uncategorized
The newly published paper by Gunnveig Grodeland et al: DNA Vaccine that Targets Hemagglutinin to MHC Class II Molecules Rapidly Induces Antibody-Mediated Protection against Influenza, describes the vaccibody platform as a robust and effective vaccine for prophylactic use. The paper can be downloaded here...
Posted at 13:56h
in
Uncategorized
In a private share issue placement in June Vaccibody raised 733.000 € from existing owners. The funding will be allocated to the company’s development of VB10.16, a therapeutic vaccine against cervical cancer.
During the last 6 months Vaccibody has obtained significant progression with conclusive data in...
Posted at 13:58h
in
Uncategorized
Please view the new presentation video by CEO Ole Henrik Brekke. Targeting vaccine technology: VB 10.16 a non-invasive treatment of cervical cancer.
...
